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Abstract
Background and Aim: Diabetic dyslipidaemia is common in type 2 diabetes (T2D) and insulin resistance and often precedes
the onset of T2D. The Taq1B polymorphism in CETP (B1 and B2 alleles) (rs708272) and the G-250A polymorphism in LIPC
(rs2070895) are associated with changes in enzyme activity and lipid concentrations. Our aim was to assess the effects of
both polymorphisms on the risk of T2D.
Methods and Results: In a case-control study from the population-based Telde cohort, both polymorphisms were analysed
by PCR-based methods. Subjects were classified, according to an oral glucose tolerance test, into diabetic (N=115) and pre-
diabetic (N=116); 226 subjects with normal glucose tolerance, matched for age and gender, were included as controls. Chi-
square (comparison between groups) and logistic regression (identification of independent effects) were used for analysis.
The B1B1 Taq1B CETP genotype frequency increased with worsening glucose metabolism (42.5%, 46.1% and 54.3% in
control, IGR and diabetic group; p=0.042). This polymorphism was independently associated with an increased risk of
diabetes (OR: 1.828; IC 95%: 1.12–2.99; p=0.016), even after adjusting by confounding variables, whereas the LIPC
polymorphism was not. Regarding the interaction between both polymorphisms, in the B1B1 genotype carriers, the
absence of the minor (A) allele of the LIPC polymorphism increased the risk of having diabetes.
Conclusion: The presence of the B1B1 Taq1B CETP genotype contributes to the presence of diabetes, independently of age,
sex, BMI and waist. However, among carriers of B1B1, the presence of GG genotype of the -250 LIPC polymorphism increases
this risk further.
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Introduction
Diabetic dyslipidaemia is characterised by hypertriglyceridae-
mia, low high-density lipoprotein (HDL) cholesterol (c) and normal
low-density lipoprotein-cholesterol (LDLc) but preponderance of
small-dense, highly atherogenic particles. The increase in free fatty
acids (FFAs) as degradation products of triglycerides (TGs) is
associated with the development of insulin resistance [1].
Cholesteryl Ester Transfer Protein (CETP) and Hepatic Lipase
(HL) are central enzymes in the metabolism of HDL particles and
reverse cholesterol transport. CETP is responsible for an exchange
of cholesteryl ester (CE) for triglycerides (TGs) between LDL and
HDL and TG rich-lipoprotein particles [2]. The result is an
enrichment of HDL and LDL particles in TGs, which makes them
good substrates for HL [3]. The latter catalyses the hydrolysis of
the TGs and phospholipids present in several lipoprotein
subclasses, leading to changes in the size and density of
lipoproteins [3]. The increased activity of either enzyme results
in lower HDLc levels and a predominance of small, dense HDL
and LDL particles [4,5].
The variations in the CETP gene, which lead to changes in
enzyme function, have consequences on lipoprotein composition.
CETP deficiency in humans is characterized by increases in
HDLc, whereas increases in its activity are associated with an
enrichment of HDL particles in TGs and a decrease in HDLc
levels [6]. The most extensively studied polymorphism in CETP is
Taq1B (rs708272) [7]. The G allele, also called B1, is associated
with higher enzymatic activity, higher CETP mass and lower
HDLc levels [8,9]. It has been estimated that this polymorphism is
responsible for 5.8% of the variation in HDLc levels [10].
Studies in transgenic mice demonstrate that the over-expression
of the gene encoding HL, Lipc, leads to a marked decrease in
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studies showing an inverse correlation between HL activity and
HDLc concentrations [12]. The -G250A LIPC polymorphism
(rs2070895) [13], located in the promoter region of the gene, has
been extensively studied in relation to enzyme activity and lipid
metabolism. The minor allele (A) is associated with a reduction of
transcriptional activity in vitro [14] and a 15–45% reduction in
enzymatic activity [15]. In humans, the minor allele has also been
associated with an increased HDLc concentration and more
buoyant LDL particles [15,16]. Studies assessing the association of
this variant with T2D show conflicting results [17].
Diabetes is often preceded and even predicted, by the presence
of dyslipidemia [13]. Thus, mechanisms involved in the develop-
ment of diabetic dyslipidemia may also play a role in the
pathogenesis of T2D. The effects of the mentioned polymorphisms
in CETP and LIPC on HDLc concentrations are well established,
but their relation with the risk of T2D is less known. Therefore, the
aim of our study was to analyze the relationship between
polymorphisms in these two genes and the presence of diabetes
and insulin resistance in a Canarian population.
Methods
Study population
The Telde study is a cross-sectional population-based study on
the prevalence of diabetes and cardiovascular risk factors in Telde,
a city located on the island of Gran Canaria, Spain. The study
population and design of this survey has been previously described
[18]. An oral glucose tolerance test (OGTT) was performed and
the subjects were classified (using ADA 1997 criteria) as diabetic
(n=115) and pre-diabetic (n=116) if they had impaired fasting
glucose, impaired glucose tolerance or both. A total of 226 subjects
with a normal OGTT were selected, after matching for gender
and age with the other two groups. All participants gave their
written informed consent for participation in the study, which was
carried out according to the declaration of Helsinki and approved
by the local ethics committee.
Genetic analyses
The biochemical analyses and insulin resistance parameters
have been described previously [19]. Genomic DNA was extracted
from whole blood (n=457) using a salting-out method. The
Taq1B CETP polymorphism was amplified by PCR-RFLP as
described by June Hsieh Wu [20] and the G-250A LIPC
polymorphism was analyzed by AMRS-PCR (Amplification
Refractory Mutation System-Polymerase Chain Reaction) [21].
Two pairs of primers were used, one which amplifies a fragment of
366 bp, common to both alleles (outer primers: 59-CTT TTC
TTT TTC TTT GGG CTT AGG CT-39 and 59-AAG ACT
GCC CAT TAA TAA TTA ACC TCT CAA-39) and another
pair specific for the SNP (inner primers): 59-CAA GGT CAG
AGT TCC AAA TTA ATC CAC-39 for the G allele and 59-TTC
CAA ACA CAA CAC AGT AGC TTT CAA-39 for the A allele.
The primers were designed ‘‘in silico’’ in a free access web (http://
cedar.genetics.soton.ac.uk, accessed in August 2007) and then
checked for specificity (http://blast.ncbi.nlm.nih.gov/Blast.cgi,
accessed in August 2007). The PCR reaction was carried out in
a total volume of 25 ml containing 1:5 ratio of outer to inner
primer concentration. The annealing temperatures were 70uC
during 15 sec for the outer primers and 58uC during 25 sec for the
inner primers with a 30 sec extension at 72uC. PCR products were
Figure 1. Agarose gel results of both polymorphisms. PCR-RFLP agarose gel (A) after digestion with Taq1B enzyme. The 1000 bp band
corresponds to the B2 allele and the 650 and 350 bp bands correspond to the B1 allele. Results of LIPC genotyping by ARMS-PCR (B). The 366 bp
band is the product of the outer primers, the 234 bp band, of an outer primer and the inner primer for allele A and the 185 bp band, of the other
outer primer and the inner primer for the G allele.
doi:10.1371/journal.pone.0027208.g001
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stained with Ethidium Bromide. This resulted in 3 DNA
fragments: one of 366 bp, one of 234 bp for the A allele and
one of 185 bp for the G allele (figure 1).
Statistical analysis
Statistical analyses were performed with SPSS for WINDOWS,
version 13 (SPSS Inc., Chicago, IL). The quantitative variables are
described as mean 6 standard deviation (S.D). Before further
analyses, variable distribution was checked with the Kolmogorov–
Smirnov test. A logarithmic transformation was performed for
variables not following a Gaussian distribution. Differences
between groups were analyzed using either analysis of variance
or analysis of covariance, both with the Bonferroni post hoc
correction test, after adjusting for age, gender, Body Mass Index
(BMI) and waist. The categorical variables were compared using
Fisher’s exact test for 262 tables and chi-squared or the Mantel-
Haenszel test for linear association. The independent contribution
of each polymorphism to DM2 risk was analyzed by a multinomial
logistic regression model, which included age, gender, BMI and
waist. All tests were considered significant if p was ,0.05.
Regarding the effect of the interaction of both polymorphisms
on the risk of diabetes, the reference category was defined by the
non-B1B1 genotype, regardless of the -250G/A LIPC genotypes
(nonB1B1CETP genotype). A second group included B1B1 and
non-GG genotypes (B1B1CETP/non-GGLIPC) and a third,
B1B1 CETP and LIPC GG genotypes (B1B1CETP/GGLIPC).
Results
Patient description
The anthropometric, clinical and genetic characteristics of the
whole population and their classification according to the OGTT
are shown in table 1. The frequencies of the B1B1, B1B2 and
B2B2 genotypes of the Taq1B CETP polymorphism in the whole
population were 46.38%, 41.57% and 12.03% respectively, while
the frequencies of GG, AG and AA genotypes of the -250G/A
LIPC polymorphism were 49.23% 43.54% and 7.22%, respec-
tively The distribution and the allele frequency of both
polymorphisms followed the Hardy-Weinberg equilibrium. Due
to very low frequencies of the 2 genotypes the B2B2 of the Taq1B
CETP and the AA of the -250G/A LIPC were analyzed in the
same category as the corresponding heterozygotic genotype,
namely as non-B1B1 (B2 carriers) and non-GG (A carriers),
respectively.
The polymorphisms and the biochemical variables
In the whole population, the B1B1 genotype carriers showed
significantly lower HDLc concentrations than the B2-allele
carriers (1.3360.30 mmol/L vs. 1.4460.33 mmol/L, p,0.001),
as well as higher glucose levels after the OGTT. In the control
population, there was a significant difference in HDLc levels
(1.3860.31 mmol/L vs. 1.5060.31 mmol/L, p=0.004; B1B1 vs.
B2-carriers, respectively) and an almost significant difference in
glucose levels after the OGTT (5.6461.08 mmol/L vs.
5.3961.29 mmol/L, p=0.069). There were no significant differ-
ences between the groups in the pre-diabetic and diabetic subjects
(data not shown).
Regarding the LIPC polymorphism, the GG genotype carriers
showed significantly higher fasting glucose concentrations than the
A allele carriers (non-GG genotype) in the whole population
(6.3062.67 mmol/L vs. 5.7961.83 mmol/L, p=0.02). However,
only the diabetic subjects showed significantly different glucose
levels after the OGTT depending on their genotype
(13.0362.72 mmol/L vs. 11.1162.94 mmol/L, p=0.025, respec-
tively).
Given the fact that the HOMA index is not a reliable estimation
of insulin resistance in diabetic subjects, this subgroup was not
analyzed separately in the analysis of variance or covariance. The
groups analyzed were: (1) the whole population, (2) the whole
population without diabetes (healthy subjects and pre-diabetic
subjects) and (3) the healthy control group. Table 2 displays the
main results obtained. In summary, B1B1 carriers of the CETP
polymorphism showed lower HDLc levels and higher HOMA and
post-OGTT glucose in all groups and higher insulin levels in the
whole population even after adjusting for confounding variables.
On the other hand, the GG genotype carriers of the LIPC
polymorphism showed higher fasting glucose levels than A-allele
carriers.
Association between CETP and LIPC polymorphisms and
the prevalence of type 2 diabetes
Figure 2 shows the frequency of each polymorphism for the
different categories of glucose tolerance (diabetic, pre-diabetic and
control groups). The frequency of the B1B1 genotype of CETP
increased with worsening glucose metabolism, whereas the GG
genotype of LIPC did not show a significant difference, although a
similar trend was found.
The independent effect of each polymorphism on the
prevalence of diabetes was assessed using a multinomial logistic
regression model adjusting for age, gender, BMI and waist. The
B1B1 genotype was associated with an increased risk of diabetes
(OR (IC95%): 1.81 (1.12–2.91); p=0.002), but not pre-diabetes
(OR (IC95%): 1.11 (0.70–1.77); p=ns). On its own, the LIPC
polymorphism was not significantly associated with the risk of
diabetes. Finally, we analyzed the effect of the interaction of both
polymorphisms on the risk of diabetes. We observed that among
the B1B1 CETP carriers, the presence of the GG LIPC genotype
increased the risk of having the disease (table 3).
Discussion
The roles of CETP and HL on lipid metabolism and reverse
cholesterol transport have been extensively described [5]. In this
study, we investigated a variant present on each gene encoding
these enzymes in relation to the risk of diabetes in a Canarian
population. Our results show that the B1B1 genotype of the
Taq1B CETP polymorphism is associated with more insulin
resistance, higher post-OGTT glucose levels and an increased risk
of T2D. On other hand, the -250G/A LIPC polymorphism is
associated with higher fasting glucose levels, but does not seem to
confer a risk of T2D by itself. However, the interaction between
both polymorphisms does have an effect on the risk of diabetes.
The Taq 1B CETP polymorphism (rs708272)
Previous studies have shown that the Taq1B CETP polymor-
phism is associated with increased enzyme activity, TG-enriched
LDL and HDL particles and low HDLc levels [9,22]. Besides, high
CETP activity has been demonstrated in obese and diabetic
subjects [23,24]. Previous studies have also shown an association
between this polymorphism and the metabolic syndrome [25],
independently of the well-known effect on HDLc concentrations
and insulin resistance [26], a fact that suggests a possible role of
CETP on glucose metabolism. However, to our knowledge, this is
the first study to show an association between this polymorphism
in CETP and the risk of T2D. The frequency of the B1B1
genotype increases with worsening glucose tolerance (figure 2) and
its presence is associated with the risk of diabetes even after
CETP, LIPC and Risk of T2D: The Telde Study
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and TG. In addition, we found lower HDLc levels in B1B1
genotype carriers, as well as higher insulin, HOMA and post-
OGTT glucose in non-diabetic B1B1 carriers, further supporting
its role in the development of T2D. Previously, we proposed that
the contribution of the Taq1B CETP polymorphism on insulin
resistance could be mediated by an increased flux of FFAs from
HDL particles to the liver. Since homozygotes for the B1 allele
have an increased CETP activity, they should have an increased
TG content in their HDL particles, which in turn would become a
good substrate for HL. Thus, individuals with the B1B1 genotype
would have an increased flux of free fatty acids to the liver from
HDL that would decrease the hepatic sensitivity to insulin [26].
The –G250A LIPC polymorphism (rs2070895)
HL catalyzes the hydrolysis of TG and phospholipids in TG-
enriched HDL and LDL particles, giving rise to smaller, denser
particles[27]. In fact, HL activity shows an inverse correlation with
HDLc concentration. Two (SNPs) have been described in the
promoter region of the gene (-514 C,T, rs1800588 and -
250G.A, rs2070895) [28], which are in almost complete linkage
disequilibrium. The minor allele in the -250A/G polymorphism is
associated with low HL activity [29], an increased HDLc
concentration[11] and more buoyant LDL particles. In fact, the
effect abdominal obesity has on HL activity is cushioned by this
allele [30]. Its frequency in our population was similar to that
found by others [13,17,31]. However, unlike other authors
[17,32], we did not find an influence of the LIPC genotype on
HDLc concentrations, nor on the risk of T2D, but it was
associated with higher glucose concentrations. The latter followed
the same direction as the results from the Finnish Diabetes
Prevention Study [13], which showed that the GG genotype
doubles the risk of progression to T2D. On the other hand, a large
Danish cross-sectional study, which included 3082 cases and 4882
controls, was negative in this aspect [33].
Taq 1B CETP and –G250A LIPC polymorphisms
The epistatic effect of CETP and LIPC on HDLc concentrations
[34,35] and atherosclerosis[35] has been previously reported. The
authors observed a marked increase in HDLc levels in carriers of
both minor frequency genotypes [35]. However, to our knowledge,
this is the first time the effect of genetic interaction between CETP
and LIPC is assessed on the risk of T2D. Since the minor allele at -
250G/A LIPC is associated with a decrease in HL activity and a
reduction of TG catabolism from HDL and LDL and the TG
content in HDL and LDL is, to a certain extent, the result of an
increased CETP activity associated to the B1B1 genotype, we
propose that the presence of the A allele of -250G/A LIPC reduced
the risk of T2D among B1B1 Taq1B CETP genotype carriers,
although the LIPC polymorphism was by itself not associated with
T2D.
One of the strengths of this study is its population-based design
including well-characterized subjects diagnosed using an OGTT
[23,24]. In addition, to our knowledge, this is the first time the
effects of CETP and LIPC are assessed in relation to the risk of
T2D. We are also aware of some limitations of the study. Its cross-
sectional nature does not allow us to infer causality. Furthermore,
our failure to identify an effect of the LIPC polymorphism on
diabetes risk might be due to sample size, as is suggested by its
association with glycemia and its significant interaction with
CETP. However, the effects we did find are likely to be true
positive, biologically plausible effects, with stringent corrections for
multiple analyses. We suggest that while the risk of T2D associated
to the B1B1 CETP genotype is a consequence of hypertriglycer-
idaemia by the increase of the flux of FFAs from HDL and LDL
particles to the liver, a decrease activity of HL associated to -250 A
Table 1. Main features of the study population.
WHOLE POPULATION
(n=457) CONTROLS (n=226) PRE-DIABETIC (n=116) DIABETIC (n=115)
Mean ± S.D Mean ± S.D Mean ± S.D Mean ± S.D
Age (y) 55.02611.09 54.48611.86 52.25612.36 58.84610,60
Sex (male/female) 226/234 104/124 57/59 65/51
BMI (kg/m2) 29.6265.00 28.6064.45 30.3065.03 30.9765.44
Cholesterol (mmol/L) 5.6561.02 5.6561.00 5.6460.91 5.6661.16
HDL-C (mmol/L) 1.3860.32 1.4560.32 1.3560.30 1.2960.31
LDL-C (mmol/L) 3.5560.87 3.5860.87 3.5360.79 3.5360.96
TG (mmol/L) 1.5560.91 1.3460.69 1.6560.91 1.8461.18
HbA1c (%) 5.7664.89 5.5166.76 5.1260.45 6.9061.80
Fasting glucose (mmol/L) 6.0462.29 4.9260.52 5.6460.66 8.6663.22
Glucose after OGTT (mmol/L) 7.1362.78 5.5061.21 8.2861.76 12.1163.22
Insulin (pmol/L) 75.4665.3 59.7638.7 76.7645.7 104.96103.1
HOMA 3.1964.17 1.9161.32 2.7561.61 5.7165.70
CETP Allele B1 67% 65% 67% 71%
Allele B2 33% 35% 33% 29%
LIPC Allele A 29% 30% 28% 26%
Allele G 71% 70% 72% 74%
Continuous variables are expressed as mean and S.D. Allele frequencies are expressed as percentages.
doi:10.1371/journal.pone.0027208.t001
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A) WHOLE POPULATION CONTROLS NON-DIABETIC POPULATION
Variables CETP Mean (IC95%) P Mean (IC95%) P Mean (IC95%) P
Fasting
Glucose
NonB1B1 5.64 (5.45–5.85) 4.86 (4.78–4.95) 5.08 (4.99–5.17)
(mmol/L) B1B1 5.91 (5.69–6.13) 0.079 4.95 (4.85–5.05) ns 5.19 (5.08–5.29) ns
Glucose
after
NonB1B1 6.38 (6.08–6.68) 5.18 (4.98–5.39) 5.92 (5.68–6.17)
OGTT
(mmol/L
B1B1 6.94 (6.60–7.31) 0.017 5.56 (5.31–5.83) 0.023 6.37 (6.08–6.68) 0.021
Insulin NonB1B1 56.7 (52.7–61.0) 46.7 (42.7–50.9) 51.8 (48.0–55.8)
(pmol/L) B1B1 63.2 (58.5–68.4) 0.047 50.9 (48.2–59.5) 0.052 57.5 (52.8–62.6) 0.068
HOMA NonB1B1 2.05 (1.51–2.23) 1.45 (1.32–1.60) 1.68 (1.55–1.82)
B1B1 2.39 (2.18–2.62) 0.017 1.69 (1.51–1.89) 0.038 1.90 (1.74–2.08) 0.039
HDL-C NonB1B1 1.39 (1.36–1.43) 1.46 (1.41–1.52) 1.42 (1.38–1.47)
(mmol/L) B1B1 1.30 (1.26–1.33) 0.000 1.33 (1.28–1.39) 0.002 1.31 (1.27–1.36) 0.001
B) WHOLE POPULATION CONTROLS NON–DIABETIC POPULATION
Variables LIPC Mean (IC95%) P Mean (IC95%) P Mean (IC95%) P
Fasting
Glucose
Non-GG 5.62 (5.42–5.82) 4.88 (4.79–4.98) 5.06 (4.97–5.16)
(mmol/L) GG 5.92 (5.71–6.14) 0.044 4.92 (4.83–5.02) ns 5.19 (5.09–5.29) 0.067
Glucose
after
Non-GG 6.67 (6.35–7.00) 5.33 (5.11–5.55) 6.08 (5.82–6.35)
OGOTT
(mmol/L)
GG 6.61 (6.28–6.95) ns 5.36 (5.13–5.60) ns 6.19(5.92–6.47) ns
Insulin Non-GG 58.9 (54.6–63.5) 47.9 (43.6–52.7) 51.8 (47.9–56.0)
(pmol/L) GG 60.3 (55.8–65.1) ns 51.5 (46.6–56.9) ns 56.8 (52.4–61.5) ns
HOMA Non-GG 2.12 (1.93–2.31) 1.49 (1.35–1.65) 1.67 (1.54–1.82)
GG 2.28 (2.08–2.50) ns 1.62 (1.46–1.80) ns 1.88 (1.73–2.05) 0.055
HDL-C Non-GG 1.35 (1.31–1.39) 1.41 (1.36–1.47) 1.38 (1.33–1.42) ns
(mmol/L) GG 1.35 (1.31–1.39) ns 1.40 (1.34–1.46) ns 1.37 (1.33–1.42) ns
P values from analysis of covariance with the Bonferroni post hoc test, after adjusting for age, gender, Body Mass Index (BMI) and waist.
doi:10.1371/journal.pone.0027208.t002
Figure 2. Distribution of Taq1B CETP and –G250A LIPC genotypes according to OGTT categories. OGTT categories are T2D: type 2
diabetes, pre-diabetes, which includes impaired fasting glucose concentrations, impaired glucose tolerance or both, and healthy controls.
doi:10.1371/journal.pone.0027208.g002
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B1B1 carriers.
In summary, the Taq1B CETP polymorphism was significantly
associated with HDLc levels and the presence of T2D and,
although we did not find the same association between the -250A/
G LIPC polymorphism and HDLc levels or T2D, the presence of
the A allele appears to exert a protective effect in B1B1 genotype
carriers in our population. Nevertheless, larger studies performed
in different populations are needed to confirm our findings.
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